Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) encourages applications for NIGMS Biomedical Technology Optimization and Dissemination (BTOD) Centers to support late-stage technology optimization and sustainable dissemination of the technologies to the wider biomedical research community. A BTOD Center should be at the leading edge of its field with respect to both technology optimization and engagement with relevant research communities.BTOD projects must address biomedical research areas within the NIGMS mission. Potential applicants are strongly encouraged to consult with NIGMS staff about adherence of their proposed research strategy to the Institute's goals and mission and its responsiveness to this NOFO.

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

All accepted applications are reviewed for scientific and technical merit by an appropriate initial review group and by a national advisory council. The goal of NIGMS funding policies is to maximize the scientific impact of investments in investigator-initiated biomedical research to drive fundamental scientific discoveries that advance understanding of human health and disease. To address this goal, the Institute strives to support a broad portfolio of research grants of high scientific and technical merit, as determined by peer review, in its mission areas. However, in deciding to fund any application, NIGMS staff also considers other factors, including (consistent with applicable law): the breadth of the Institute�s research portfolio; approaches, and investigators; the total amount of funding available to the investigator; the priority of the research area for the Institute�s mission; Early-stage investigator status; At-risk investigator status?;? and whether the PI would have more than one NIGMS funded R01 (including multi-PI R01s). Because these factors are considered, NIGMS does not have a �payline� or strict cutoff in scores that it will fund. It is important to understand that even applications with outstanding scores might not be funded if the investigator already has substantial other support. Because NIGMS prioritizes funding for meritorious investigators who otherwise would not have support over providing additional grants to already well-funded...